ImmunityBio, Inc. (IBRX)
| Market Cap | 8.57B +267.9% |
| Revenue (ttm) | 82.56M +1,026.0% |
| Net Income | -348.62M |
| EPS | -0.42 |
| Shares Out | 984.97M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 45,429,760 |
| Open | 8.63 |
| Previous Close | 8.61 |
| Day's Range | 8.32 - 9.25 |
| 52-Week Range | 1.83 - 9.25 |
| Beta | 0.02 |
| Analysts | Strong Buy |
| Price Target | 11.80 (+35.63%) |
| Earnings Date | Mar 4, 2026 |
About IBRX
ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company’s platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA... [Read more]
Financial Performance
In 2024, ImmunityBio's revenue was $14.75 million, an increase of 2270.58% compared to the previous year's $622,000. Losses were -$413.56 million, -29.09% less than in 2023.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for IBRX stock is "Strong Buy." The 12-month stock price target is $11.8, which is an increase of 35.63% from the latest price.
News
ImmunityBio Partners with Biopharma and Cigalah Healthcare to Launch ANKTIVA® in Saudi Arabia for Bladder and Lung Cancer Patients
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced a partnership with Biopharma and Cigalah, two of the largest and most ...
ImmunityBio Holds Golden Cross As Stock Trades 170% Above 200-Day Average
ImmunityBio Inc (NASDAQ: IBRX) stock is maintaining a confirmed Golden Cross, with the stock now trading roughly 170% above its 200-day moving average — a measurable signal of sustained long-term tren...
ImmunityBio Expands Access to ANKTIVA® in EU with New Distribution Partnership and Opens Irish Subsidiary to Support European Launch
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced a partnership with Accord Healthcare to provide access to ANKTIVA® (no...
What's Behind The Jump In ImmunityBio Stock?
The authorization by the European Commission allows ImmunityBio to establish a substantial commercial footprint across four regulatory jurisdictions in less than two years from its initial FDA approva...
ImmunityBio Receives Authorization from the European Commission for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ, Expanding Global Access to 33 Countries
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the European Commission has granted conditional marketing authorization...
ImmunityBio: The Story Surrounding Anktiva So Far
ImmunityBio commands a premium valuation on the promise of Anktiva, a chemo-free immunotherapy platform showing early efficacy and manageable safety. IBRX's Anktiva is FDA-approved for BCG-unresponsiv...
ImmunityBio Reports Productive Regulatory Engagement with Saudi Food and Drug Authority at USA-Saudi Biotech Alliance Meeting Hosted by the Ministry of Investment of Saudi Arabia
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NYSE: IBRX), a commercial stage immunotherapy company developing next generation therapies that drive immunological memory and restore immune c...
ImmunityBio Launches Phase 2 Chemotherapy-Free CAR-NK Cell Therapy Trial with ANKTIVA® (ResQ215B) in Indolent Lymphomas
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the launch of ResQ215B, a Phase 2 clinical study evaluating a novel ch...
ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA® Plus CAR-NK, Chemo-Free Therapy
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company developing cytokine and cellular immunotherapies designed to restore immune competence,...
FDA Talks Set Path For Expanded Use For ImmunityBio's Anktiva In Bladder Cancer
ImmunityBio Inc. (NASDAQ: IBRX) on Tuesday said it plans to submit additional information to the U.S. Food and Drug Administration (FDA) within 30 days following a Type B end-of-phase meeting related ...
Top 3 Health Care Stocks You May Want To Dump In January
As of Jan. 20, 2026, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA® in BCG-Unresponsive Papillary Bladder Cancer
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that it recently held a Type B End-of-Phase meeting with the U.S. FDA re...
ImmunityBio, Inc. (IBRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
ImmunityBio, Inc. (IBRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
ImmunityBio Stock Soars On Cancer Trial Progress, FDA Timeline
ImmunityBio Inc. (NASDAQ: IBRX) stock has surged more than 100% year to date after the upbeat fourth-quarter preliminary results and trial data.
ImmunityBio's 700% Revenue Boom Becomes Citadel's Latest I‑Told‑You‑So
Hedge funds don't need headlines to move — they need inflection points. ImmunityBio Inc (NASDAQ: IBRX) just delivered one.
ImmunityBio Announces Durable Complete Response of 15 Months with a Chemotherapy-Free CD19 CAR-NK Cell Therapy in Waldenstrom Lymphoma
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced updated efficacy and safety results from the ongoing QUILT-106 clinica...
ImmunityBio Advances First-Line BCG Naive NMIBC Program with Enrollment Exceeding Expectations and Positive Interim Analysis for ANKTIVA® Plus BCG
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) today announced an update on the status of enrollment in its randomized registrational trial in BCG-naïve non-muscle-invasive bla...
This Biotech Stock Is Up 100% This Year. Why It's Soaring Again Today.
The shares have climbed on every trading day so far in 2026. The streak looks set to continue.
ImmunityBio: Why I Am Upgrading To A Buy For 2026
ImmunityBio is upgraded to Buy for 2026, reflecting improving Anktiva data and potential label expansions in NMIBC and NSCLC. IBRX reported 2025 product revenue of $113m, up 700% year-on-year, but los...
ImmunityBio Clocks 700% Revenue Surge In 2025 From Lead Bladder Cancer Drug
ImmunityBio, Inc. (NASDAQ: IBRX) shares are up on Thursday as the company is reporting continued execution and sales momentum, with a significant increase in preliminary net product revenue.
ImmunityBio Reports Continued Execution and Sales Momentum With $113 Million of Preliminary Net Product Revenue—a 700% increase year-over-year
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a vertically-integrated commercial stage biotechnology company, announced today preliminary select operational results for the f...
Saudi FDA Grants Accelerated Approval to ImmunityBio's ANKTIVA® In Combination with Checkpoint Inhibitors for Metastatic Non-Small Cell Lung Cancer
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the Saudi Food and Drug Authority (SFDA) has granted accelerated ...
Saudi FDA Grants Accelerated Approval to ImmunityBio's ANKTIVA® for Non-Muscle Invasive Bladder Cancer with Carcinoma In-Situ
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the Saudi Food and Drug Authority (SFDA) has granted approval of ...